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Abstract
Mast cells are tissue resident, innate immune cells that provide protection against parasitic and
bacterial infections and venom poisoning. Mast cells also play a pathogenic role in atopy and
allergic diseases. Atopy and allergic diseases are increasing in the developed world and are
predicted to continue to increase at an alarming rate. Current treatment options include
corticosteroids, anti-histamines, anti-IgE and avoidance of allergen. These interventions have
limitations: some patients are steroid resistant; anti-histamines have low efficacy since they
need to be administered early during allergen exposure; and anti-IgE is costly. Thus there is a
clinical need for new treatment options. An efficient approach is to re-purpose FDA-approved
drugs. Selective serotonin reuptake inhibitors (SSRIs) are a class of anti-depressants used to
treat depression and other psychiatric disorders. SSRIs have been shown to possess antiinflammatory properties, but the mechanism of action is unclear. The possibility to treat allergic
diseases with SSRIs has not been studied. Using primary mouse bone marrow derived, ex vivo
cultured mouse peritoneal, and primary skin derived human mast cells, we show that the SSRI
fluoxetine suppresses IgE-mediated degranulation, cytokine production, and inflammatory lipid
secretion. Several other SSRIs showed similar effects on mouse mast cells. Cytokine suppression
occurs at a transcriptional level, as evidenced by decreased signaling downstream of the IgE
receptor and reduced cytokine mRNA induction. We found that fluoxetine-mediated
suppression requires the purinergic receptor, P2X3. Furthermore, we show that IgE stimulation
elicits rapid ATP release from mast cells, and that ATP and purinergic signaling is a positive
feedback regulator of mast cell activation. Fluoxetine can also suppress ATP-mediated cytokine
production, degranulation, and lipid production most likely via NFb suppression and

vii

diminished purinergic receptor expression. Importantly, fluoxetine effects are consistent in an
in vivo passive systemic anaphylaxis (PSA) model and in a house dust mite (HDM) airway
hyperresponsiveness and lung inflammation model of asthma. In the PSA model, fluoxetine
reduced hypothermia and cytokine production. In the asthma model, the drug suppressed
bronchoresponsiveness as well as pulmonary mast cell hyperplasia and eosinophilia, and the
recruitment of Th2 cells, neutrophils, eosinophils, and lymphocytes to the bronchoalveolar
space, as well as cytokine levels in the bronchoalveolar fluid in sensitized mice. Overall, we
show that fluoxetine broadly suppresses mast cell activation in vitro and in vivo, most likely by
impeding an ATP-P2X3 positive feedback loop.
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Chapter 1: Introduction

Brief Introduction to The Immune System
Immunity is a complex system that protects the host against pathogenic organisms,
toxins, and cancerous growth. Although it is necessarily complex, the classical categorization of
the immune system involves two arms, the adaptive and innate. The adaptive immune system
largely consists of antigen-activated T helper cells priming B cells and cytotoxic T cells to
differentiate into the mature, activated states. B cells differentiate into immunoglobulin (Ig)
producing plasma cells. Immunoglobulin facilitates pathogen recognition and destruction.
Because the cells involved generate long-lived, antigen-specific memory cells, the adaptive
response provides protection from re-infection. But because this response can require a week
to be fully functional during a first time exposure, a less specific and more rapid system is also
needed to protect the host.
The innate immune system reaction time is quick and non-specific. Neutrophil function
is a vital example of innate immunity. Neutrophils can respond to common bacterial products,
such as LPS, and release reactive oxygen species (ROS) and toxins to broadly kill other cells in
the micro-environment1. Mast cells are an innate immune cell that serves as a bridge to
adaptive immunity (fig.1)2. In addition to responding to common bacterial products, mast cells
bind IgE and IgG immunoglobulins through expression of FcεRI and Fcγ receptors, which
stimulate mast cell function. They also express TLRs, ST2, many cytokine receptors, and
purinergic receptors that respond to innate signals independent of immunoglobulins3–5.
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IgE-mediated mast cell activation is the most studied area of mast cell biology and likely
the most clinically relevant. Parasitic infection induces a strong Th2 and ILC2 cell response,
leading to IL-4 and IL-13 secretion that instructs B cells to secrete IgE6. IgE and mast cells play a
key role parasitic clearance. Because parasitic infection is a strong evolutionary pressure and is
still very common in undeveloped countries, the Th2-IgE-mast cell response is well ingrained in
humans. However, IgE is also made against non-pathogenic environmental antigens termed
allergens, which are the driving force behind the widespread occurrence of allergic disease in
the developed world. In first world nations, mast cells are mostly studied in the context of their
pathologic involvement in allergic diseases. In the US alone, 19 million adults and 6.2 million
children have asthma and 25.5 million people were diagnosed with hay fever in 2017 7 8 9.

Mast cells and their role in allergy and asthma
Mast cells were first described nearly 140 years ago by Paul Ehrlich10. He named these
aniline dye-positive cells “mastzellen” with the belief that these cells served a phagocytic
function due to their high granularity. Mastzellen means cells that eat or to ingest in German,
Paul Ehrlich’s native language. Many years later, it was discovered that the granular contents
reacting to the aniline dye were heparin and histamine and that both are released during
anaphylactic shock. Early studies were conducted with compound 48/80 since IgE and FcεRI
were not yet discovered. Mast cell involvement in allergic disease is now well documented as
typically occurring through IgE-dependent mechanisms.
The identification of IgE and its binding to the high affinity receptor on the mast cell
surface in the late 1960’s-early 1970’s by the Ishizakas and others laid the ground work for
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studying IgE-mediated mast cell and basophil activation and allergies11,12. Following this
discovery, other pro-inflammatory mediators released by IgE-activated mast cells were found.
Stimulated mast cells were shown to produce the cytokines IL-3, IL-4, IL-5, IL-6, GM-CSF, and
TNF, a list that continues to grow13 14 15 . Products of arachidonic acid metabolism, leukotrienes
and PGD2, were shown by Frank Austen and others to be released from mast cells during
anaphylactic shock, through IgE-dependent mechanisms16 . Mast cells were also shown to
produce specific proteases (MCP) called tryptase and chymases 17 18. These proteases play a key
role in innate protection against snake venom, parasitic and even bacterial infections19,20,5. The
production of eicosanoids, proteases and other mediators vary based on the tissue of origin,
leading to the characterization of connective tissue and mucosal mast cells in mice and MCT
(tryptase+) and MCTC (tryptase/chymase+) mast cells in humans21. Thus mast cells are
heterogenous and adaptable for optimal function based on their environment.
The discovery of IgE led to the characterization of its receptor. The first identified IgE
receptor, FcεRI, is present at a high numbers on human and mouse mast cells at ~3-500,000
receptors per cell and binds IgE with high affinity. It is a tetrameric receptor with α, β, and 2
disulfide-linked γ subunits in mice and humans. Human mast cells also have a trimeric version
lacking the β chain that is expressed more broadly on innate immune cells (Figure 2)22. FcεRI
aggregation, typically via IgE and antigen, induces a biochemical signaling cascade that leads to
the synthesis and/or release of pro-inflammatory products and modulators of allergic disease
and parasitic infections.
The FcεRI β and γ chains contain immunoreceptor tyrosine-based activation motifs
(ITAMs) with two tyrosine residues. These residues become phosphorylated by Lyn and Fyn
3

after aggregation, serving as docking site for Syk on the γ chains 23. Syk is then activated mainly
via autophosphorylation, since binding to the ITAMs causes a conformational change increasing
its enzymatic activity24,25 26. Fully activated Syk then activates the scaffold adaptors LAT1 and
LAT3 which then activates the PI3K and BTK. Together, this pathway leads to the activation of
Akt and phospholipase C which hydrolyzes membrane phosphatidylinositol 4,5-triphospate
(PIP2) in the membrane creating the products diacylglycerol (DAG), which activates protein
kinase C, and inositol 1,4,5-triphospahte (IP3) which releases ER calcium stores. ER calcium
depletion activates the calcium release activated channel (CRAC), which elicits a large calcium
influx through the cell membrane. This signaling cascade leads to degranulation within minutes
and is the etiology of the “immediate” allergic response.
Mast cell cytokine secretion is part of the “late” allergic response that occurs within
hours. This process is also activated partly by calcium flux with additional signals through
several kinase cascades including PI3K and MAPK. These converge on transcription factors,
including NFB, NFAT, AP-1, and Stats. The MAP kinase and PI3K pathways also activate
phospholipase A2, which cleaves membrane lipids, beginning the synthesis of arachidonic acid
metabolites. There are also negative regulators involved in controlling this biochemical
pathway, mainly phosphatases. Lyn can also be involved in negative regulation, giving it a dual
role27. These integrated pathways are summarized in Figure 322.
IgE also has a low affinity receptor, CD23, which has an unusual trimeric C-type lectin
structure. This receptor plays an important regulatory role in the production of IgE, since its
expression on B cells limits IgE production28. CD23 is cleaved from the membrane by
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metalloproteases, thus many groups are investigating the inhibition of these metalloproteases
as a therapeutic option to block the production of IgE.
In keeping with their innate immunity function, mast cells can also become activated
independently of IgE. This allows mast cells to participate in physiological processes outside
allergies and type 2 immunity. In the 1990’s, mast cells were shown to be critical for the
clearance of bacteria and protection against sepsis through the production of TNF induced by
bacterial Fimbrial protein 30 31. Mast cells have also been shown to accumulate in response to
viral infections although their role is not fully elucidated32. In addition to pathogen–associated
molecular patterns (PAMPs), mast cells respond to damage/danger-associated molecular
patterns (DAMPs). Via expression of ST2, mast cells respond to the alarmin IL-3333,34. They also
express P2X receptors which respond to the DAMP extracellular ATP 4,35. Though DAMPmediated functions can occur separate from IgE-induced activation, there is now ample
evidence that DAMPs exacerbate allergic disease partly by enhancing IgE-mediated mast cell
function36,37.

Allergic Asthma
Allergic asthma is characterized by Th2-type lung inflammation, airway remodeling,
airway hyperresponsiveness, increased mucus production and airway obstruction. The evidence
for mast cell involvement in asthma includes pulmonary mast cell hyperplasia and high levels of
leukotrienes, tryptase, chymase, and histamine in the sputum and bronchial alveolar lavage
fluid of asthmatics38,39–41.
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Anti-IgE treatment is effective in ~60% of asthmatics, supporting the involvement of IgE
and mast cells in human asthma42. Despite this, earlier reports using mouse models claimed
that mast cells and IgE are not important for AHR or allergic lung inflammation. However more
recent reports show that this is highly dependent on the choice of antigen (OVA vs. HDM),
duration of sensitization, route of sensitization (intraperitoneal vs. intranasal), use of adjuvant,
and amount of antigen exposure. The use of large amounts of antigen bypasses mast cell
involvement but this also depends on duration of exposure43. The strain of mice used has also
been suggested to influence mast cell involvement44. Although the use of mouse models does
not fully replicate human disease, these models have contributed to the expansion of our
knowledge of allergic asthma in the past few decades. With a clearer understanding of how to
manipulate mouse models to involve most aspects of human asthma, we have more
information about the role of mast cells in asthma. We know that the presence of mast cells
exacerbates AHR and lung inflammation 45 46. Further, eosinophil recruitment is impaired in
Kitwsh/wsh mice which lack mature mast cells, suggesting that mast cells are important in
pulmonary eosinophilia47. Mast cell activation causes increased airway hyperresponsiveness to
methacholine48. Mast cells have also been shown to possibly control allergic lung
inflammation, for example the protective role of PGE2 in the lung has been shown to be driven
through mast cell leukotriene receptors. Overall, the literature and evidence from the clinic
suggest that mast cells are a viable target for allergic asthma treatment.
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Purinergic signaling
Purinergic signaling involves two subclasses of trimeric receptors, P2X and P2Y. P2X
receptors are ligand-gated ionotropic channels, while P2Y are G-protein coupled metabotropic
receptors. P2X receptors bind ATP, while P2Y proteins interact with ATP and a range of other
purine-based ligands. There are 7 known P2X receptors (P2X1-P2X7), and 8 P2Y receptors.
Examining gene knockout (KO) phenotype shows that P2Y receptors have overlapping
functions, since KOs have mild phenotypes. In contrast, P2X KO mice show prominent
phenotypes, suggesting unique contributions. P2X7 is the most extensively studied in the
context of immunity. P2X7 signaling is important for T cell differentiation into Th1 and Th2,
neutrophil and macrophage migration, synthesis and release of IL-1beta, and inflammasome
formation49 50 51. P2X2-4 have also been shown to play important immunoregulatory roles. Mice
deficient in P2X4 had decreased eosinophilia in BAL fluid, as well as decreased Th2 cytokines
following allergen-induced airway inflammation52 . P2X2 and P2X3 KO mice had increased
susceptibility to infection and increased immune cell infiltration into the spleen, resulting in
splenomegaly53. P2X receptors are expressed on most cells of the innate and adaptive immune
system. Human mast cells have been shown to express mRNA for P2X1, 4 and -74 35. Mast cell
P2X receptors elicit calcium influx and cytokine/chemokine release upon ligation by ATP 4.
Furthermore, ATP signaling through P2X7 on mast cells was shown to be critical in a murine
colitis model and human Crohn’s disease through induction of IL-33 release36. These data
suggest that mast cell purinergic signaling is a viable therapeutic target for allergic disease.
P2X3 is more extensively studied in the context of neuropathic pain, although some
immunological functions have been suggested. For example, colonic tissue has increased P2X3
expression in patients with inflammatory bowel syndrome54. Also human peripheral blood
7

leukocyte and primary human B cells have been reported to express P2X3, albeit in smaller
amounts compared to other P2X receptors55,56. P2X3/P2X2 are commonly known to
heterodimerize; P2X3/P2X2 DKO mice fail to induce a proper immune response and thus are
more susceptible to various infections. Human P2X3 has been crystalized, allowing further
structural insight of this membrane receptor57. Several unique features of P2X3 were revealed
by this crystallization such as a “cytoplasmic cap” that acts as an anchor in the open/active
state. This study also revealed that P2X3 needs a Mg2+ binding pocket in close proximity to the
ATP binding regions. Currently P2X3 antagonists are being investigated for treatment of
rheumatoid arthritis, chronic pain and refractory cough58,59. There is very little known about
P2X3 function on mast cells. Our study results suggest that it is positive regulator of IgEmediated mast cell activation.

Selective serotonin reuptake inhibitors
Selective serotonin reuptake inhibitors (SSRIs) are a class of anti-depressants. Five SSRIs that
are included in this study are pictured in Figure 4, adopted from the PubChem database. It has
been noted that anti-depressant use correlates with anti-inflammatory effects. For example, a
meta-analysis of studies examining serum cytokine levels before and after treatment of
patients diagnosed with major depressive disorder found that SSRI treatment reduced serum
TNF and IL-660. A study examining the relationship between depression, SSRI treatment and
IFNɣ levels in patients with the comorbid diagnoses of major depression and multiple sclerosis
(MS) found that SSRI treatment led to decreased IFNɣ production, which is corroborated by a
study showing that SSRI treatment can reduce the onset of experimental MS61 62. Several other
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studies demonstrate the anti-inflammatory properties of SSRIs63–65. Furthermore, there is
increasing evidence that blocking inflammatory pathways reduces symptoms of major
depression and other psychiatric disorders, which can be associated with anti-depressant use.
This contributes to the evidence of a substantial link between inflammation and depression66 67
68 69

. More interesting for our work, a trial aimed at studying the safety of administering SSRIs

to asthmatics found the SSRI group to have decreased need for corticosteroid use, an important
measure of asthma severity70. This indicates that SSRIs may be a therapeutic option for
asthmatics.
Although these data show that SSRIs have anti-inflammatory effects, the mechanism is
unclear and could reveal novel drug targets for allergic disease. While SSRIs are designed to
inhibit the serotonin transporter (SERT), recent work has indicated that paroxetine can inhibit
P2X7 and P2X471 72. There are also differences between SSRIs. For example, paroxetine can
inhibit P2X7 but fluoxetine and desipramine cannot73. These data suggest that there is an offtarget effect of SSRIs that is beneficial for asthma treatment and that differences between SSRIs
could occur.

9

Figure 1 Mast cells contribute to innate as well as adaptive immune responses.
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Figure 2: IgE and Its High Affinity
Receptor. IgE binds the alpha chain portion
of its high affinity receptor at the Fc portion
of the immunolglobulin. The FcERI is made
up of an alpha chain, a beta chain and two
gamma chains. Adopted from Siraganian
et.al.20
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Figure 3: IgE Signaling Cascade. The most well studied stimuli of mast cells is through IgE and FcRI. Once IgE on the cell
surface is crosslinked with antigen, receptor dimerization initiates a signaling cascade requiring of Lyn, Fyn, Syk etc. Signals
needed for calcium influx and then degranulation occur within minutes. Signals for activation of transcription factors then
follow and cytokines are transcribed and released within hours of antigen exposure.
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Fluoxetine

Sertraline

Paroxetine

Fluvoxamine

Citalopram

Figure 4: SSRI Chemical Structures. Fluoxetine, paroxetine, fluvoxamine, sertraline, and citalopram
are all selective serotonin reuptake inhibitors. Images adapted from Pubchem database.
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Chapter 2: Methods
Mouse mast cell culture:
Bone marrow derived mast cells (BMMCs) were derived from marrow collected from mice
femurs. Red blood cells were lysed with ACK lysis buffer. Cells were plated in RPMI (Invitrogen
life technology) with 10% FBS (Sigma), 2mM L-glutamine, 100 U/ml penicillin, 100 ug/ml
streptomycin, 5ug/ml ciprofloxacin, 1 mM sodium pyruvate and 1mM HEPES buffer. WEHI
supernatant containing 3ng/mL IL-3, and BHK-MKL supernatant containing 15 ng/mL SCF was
added to the growth medium. Cells were cultured for 21 days at which point cells were 90%
cKit/FcRI-positive and ready for experimentation. Peritoneal mast cells (PMCs) were cultured
the cRPMI with 10 ng/ml IL-3 and SCF for 7-10 days.

Mouse basophil culture:
Mouse bone marrow-derived basophils were cultured in cRPMI with 20ng/mL recombinant IL-3
for 7-10 days, and selected for basophils with anti-CD49b (Biolegend clone HMα2).

Mouse eosinophil culture:
Mouse bone marrow-derived eosinophils were grown in RPMI with Glutamax (Invitrogen), 20%
FBS, 25mM HEPES, 100 U/mL penicillin, 100ug/mL streptomycin, 1X NEAA, 55 M βME,
supplemented with 100ng/ml SCF and 100ng/mL FLT-3 (Shenandoah Inc) for 4 days and then
10ng/mL IL-5 (Shenandoah Inc). On day 12 of culture, cells were 90% SiglecF-positive and
ready for experimentation74(BD Bioscience clone E50-2440).
14

Human skin mast cells:
All protocols involving human tissues were approved by the human studies Internal Review
Board at the University of South Carolina or Virginia Commonwealth University. Cells were
cultured as previously described75. Human skin mast cells were cultured with 10M fluoxetine,
1 g/ml mouse IgE, and human recombinant SCF for 24 hours. Cells were washed and re-plated
with fluoxetine, SCF and 50 ng/ml DNP for 16 hours. Supernatant was collected for cytokine
analysis by ELISA.

Animals:
C57BL/6, 129/SvJ, Balb/cJ, and B6.129(Cg)-Slc6a4tm1Kpl/J (SERT KO) mice were purchased from
Jackson Laboratory, bred and maintained at the VCU animal facilities. All animal care and uses
were approved by the Virginia Commonwealth University Institutional Animal Care and Use
Committee (IACUC). All animals in this study were females unless otherwise stated.

Supernatant Cytokine Measurement:
BMMCs were treated with SSRIs or vehicle at 1x106 cells/mL in cRPMI with 10ng/mL IL3 and SCF
with 0.5ug/mL anti-DNP IgE for 24 hours. Some experiments were done with pre-sensitized
BMMCs as indicated in figure legends. Cells were then washed and re-plated with fluoxetine
and 50ng/mL DNP-HSA for 16 hours. Other BMMCs treated with fluoxetine for 24 hours were
activated with 150M ATP for 4 hours. Supernatant was collected and analyzed for IL-13, MIP1 (CCL-3; Peprotech), IL-6, MCP-1 and TNF (Biolegend) by ELISA as instructed by manufacturer.
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Degranulation:
IgE-sensitized BMMCs were treated with fluoxetine for 24 hours, washed, and stimulated with
50 ng/ml DNP-HSA with fluoxetine present for 30 minutes. Cells were placed on ice and washed
in ice cold PBS. Cells were stained with anti-CD107a and anti-CD63, then analyzed using a
FACSCelesta.

RT-qPCR:
Cells treated +/- fluoxetine were stimulated with IgE crosslinkage as described above for 4
hours. Trizol (Life Sciences) was used to extract total RNA. Nucleic acid purity was measured
using a Nanodrop 1000 UV-Vis Spectrophotometer (Thermo Scientific). To measure mRNA
expression, cDNA was synthesized using the qScript cDNA Synthesis Kit (Quanta Biosciences)
following the manufacturer’s protocol. qPCR analysis was performed with Bio Rad CFX96
Touch™ Real-Time PCR Detection System and SYBR® Green detection using a relative Livak
Method. Reactions consisted of a heat-activation step at 95 °C for 10 min followed by 40 cycles
of 95 °C for 15s, 55 °C for 30s and 60 °C for 1 min. Fluorescence data were collected during the
extension step of the reaction. Primers for IL-6 (forward: 5′TCCAGTTGCCTTCTTGGGAC3′,
reverse: TCCAGTTGCCTTCTTGGGAC3′), β-actin (forward: 5′GATGACGATATCGCTGCGC3′,
Reverse: 5′CTCGTCACCCACATAGGAGTC3′) and IL-13 (forward:
ATGGCGTCTGGGTGACTGCAGTCC’, Reverse: GAAGGGGCGTGGCGAAACAGTTGC) were
purchased from Eurofins.
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Drugs and Inhibitors:
Fluoxetine, paroxetine, fluvoxamine, citalopram and sertraline were purchased from Sigma
Aldrich. Serotonin, RO-3, TCP262, 5BDB, A70003, and NF449 were purchased from Tocris.
Propidium Iodine exclusion staining of mast cells and flow cytometry was used to determine
toxicity of all drugs before use. P2X inhibitors were used in the concentration range
recommended by manufacturer for specificity.

Intracellular Cytokine Staining:
Basophils or BMMCs were treated with IgE and fluoxetine as previously described, crosslinked
with DNP-HSA for 2 hours, then treated with 5M monensin for 5 hours. Cells were fixed in 4%
paraformaldehyde for 20 minutes at room temperature and stored in PBS overnight at 4C. The
next day, fixed cells were permeabilized in saponin buffer for 20 minutes at room temperature
and then stained in saponin buffer at 4C for 40-60 minutes with fluorochrome-labeled anti-IL6
( BD Bioscience clones MP5-20F3), anti-TNF (BD Bioscience clone MP6-XT22), anti-MCP
(Biolegend clone 2H5), anti-IL4 (BD Bioscience clone 11B11 or anti-IL13 (BD Bioscience JES105A2).

Mass Spectrometry for Lipid Detection:
BMMCs were treated with IgE and fluoxetine as previously described and activated with
50ng/mL DNP-HSA or 150M ATP for 1 hour. Supernatant were stored at − 80 °C until the time
of analysis. Lipids were extracted for eicosanoids. Eicosanoid Preparation-Eicosanoids were
extracted using a modified extraction process from previously described76,77. 4 mL of media was
combined with an IS mixture comprised of comprised of 10% methanol (400 μl), glacial acetic
17

acid (20 μl), and internal standard (20 μl) containing the following deuterated eicosanoids (1.5
pmol/μl, 30 pmol total) (All standards purchased from Cayman Chemicals): (d4) 6ketoProstaglandin F1α, (d4) Prostaglandin F2α, (d4) Prostaglandin E2, (d4) Prostaglandin D2, (d8) 5Hydroxyeicosa-tetranoic acid (5-HETE), (d8) 12-Hydroxyeicosa-tetranoic acid (12-HETE) (d8) 15Hydroxyeicosa-tetranoic acid (15-HETE), (d6) 20-Hydroxyeicosa-tetranoic acid (20-HETE), (d11)
8,9 Epoxyeicosa-trienoic acid, (d8) 14,15 Epoxyeicosa-trienoic acid, (d8) Arachidonic acid, (d5)
Eicosapentaenoic acid, (d5) Docosahexaenoic acid, (d4) Prostaglandin A2, (d4) Leukotriene B4,
(d4) Leukotriene C4, (d4) Leukotriene D4, (d4) Leukotriene E4, (d5) 5(S),6(R)-Lipoxin A4, (d11) 5iPF2α-VI, (d4) 8-iso Prostaglandin F2α, (d11) (±)14,15-DHET, (d11) (±)8,9-DHET, (d11) (±)11,12DHET, (d4) Prostaglandin E1, (d4) Thromboxane B2, (d6) dihmo gamma linoleic acid, (d5)
Resolvin D2, (d5) Resolvin D1, (d5) Maresin 2, and (d5) Resolvin D3. Samples and vial rinses (5%
MeOH; 2 ml) were applied to Strata-X SPE columns (Phenomenex), previously washed with
methanol (2 ml) and then dH2O (2 ml). Eicosanoids eluted with isopropanol (2 ml), were dried
in vacuuo and reconstituted in EtOH:dH2O (50:50;100 μl) prior to UPLC ESI-MS/MS analysis.
Liquid chromatography/mass spectrometry: Analysis of Eicosanoids by UPLC ESI-MS/MSEicosanoids were separated using a Shimadzu Nexera X2 LC-30AD coupled to a SIL-30AC auto
injector, coupled to a DGU-20A5R degassing unit in the following way. A 14 min. reversed phase
LC method utilizing an Acentis Express C18 column (150mm x 2.1mm, 2.7µm) was used to
separate the eicosanoids at a 0.5 ml/min flow rate at 40°C. The column was equilibrated with
100% Solvent A [acetonitrile:water:formic acid (20:80:0.02, v/v/v)] for 5 min and then 10 µl of
sample was injected. 100% Solvent A was used for the first two minutes of elution. Solvent B
[acetonitrile:isopropanol:formic acid (20:80:0.02, v/v/v)] was increased in a linear gradient to
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25% Solvent B at 3 min., to 30% at 6min., to 55% at 6.1min., to 70% at 10 min., to 100% at
10.10min., 100% Solvent B was held constant until 13.0min, where it was decreased to 0%
Solvent B and 100% Solvent A from 13.0min to 13.1min. From 13.1min to 14.0 min. Solvent A
was held constant at 100%. Eicosanoids were analyzed via mass spec using an AB Sciex Triple
Quad 5500 Mass Spectrometer. Q1 and Q3 were set to detect distinctive precursor and product
ion pairs. Ions were fragmented in Q2 using N2 gas for collisionally-induced dissociation.
Analysis used multiple-reaction monitoring in negative-ion mode. Eicosanoids were monitored
using precursor → product MRM pairs, which can be found in Supplementary Table S5. The
mass spectrometer parameters used were: Curtain Gas: 20 psi; CAD: Medium; Ion Spray
Voltage: -4500 V; Temperature: 300 °C; Gas 1: 40 psi; Gas 2: 60 psi; Declustering Potential,
Collision Energy, and Cell Exit Potential vary per transition.

Passive Systemic Anaphylaxis:
Female mice were sensitized with 50g IgE and treated with PBS or fluoxetine at 1mg/Kg
intraperitoneally. The next day, mice were given a second injection of PBS or fluoxetine. Base
core body temperature using rectal thermometer (Braintree Scientific Inc) was recorded. 2
hours later mice received 100g DNP-HAS by IP injection. Core body temperature was recorded
every 10 minutes for 1 hour and then every 30 minutes for 1 hour for a total of 2 hours. Mice
were sacrificed using CO2 asphyxiation as approved by the VCU IACUC. Peritoneal lavage was
collected with PBS+5mM EDTA and cardiac puncture was performed. Lavage cells were stained
with Zombie aqua dye (Biolegend), anti-CD45 (BD Bioscience clone 30-F11), anti-cKit (BD
Bioscience clone ACK45), and anti-FcεRI (Biolegend clone MAR-1). Cell counts were determined
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by Precision Counting Beads (BD) by manufacturer’s instructions. Plasma cytokine levels were
determined using IL-13 and MIP-1 ELISA kits from Peptrotech, and IL-6 ELISA kit from Biolegend.
Plasma histamine levels were determined using Neogen Histamine Kit. Histamine-induced
anaphylaxis was elicited by IP injection of 5mg histamine.

Flow Cytometry:
For direct surface markers, cells were blocked with anti-CD16/CD32 clone 2.4G2 and stained at
4C for 20-30 minutes. For intracellular staining, Cells were fixed in 4% formaldehyde at room
temperature for 30 minutes and stored overnight in PBS at 4C . The next day, cells were
permeabilized with saponin buffer for 20 minutes and stained with rabbit anti-P2X3 (Novus
Biologicals LLC NB100-1654 or Abcam ab90905) or rabbit isotype IgG, then washed and stained
with PE-coupled Donkey anti-rabbit IgG (Biolegend). All flow data was acquired using
FACSCelesta and analyzed by FACS Diva or FlowJo software. Flow cytometry with BMMCs were
gated on high FSC and SSC and singlets. Further gates are determined using isotype and FMO
controls.

Intracellular Calcium Flux Assay:
BMMCs were treated -/+ fluoxetine and IgE for 24 hours. Cells were washed and loaded with
fura2 AM (Thermofisher) at 37C for 40 minutes. Cells were washed and plated in Tyrode’s
buffer with 1% FBS, 10ng/mL IL-3 and SCF -/+ fluoxetine. Cells were allowed to rest at room
temperature for 30 minutes and 37C for 10 minutes. Cells were activated with 150M ATP,
50ng/mL DNP-HSA or 10M ionomycin. Some samples received DNP-HSA and fluoxetine
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together. Cells were analyzed using a Flexstation plate reader (Molecular Devices). Data were
collected every 4 seconds and reported as a ratio of 340/380 nm excitation detected at 510 nm
emission.
NFκB reporter activity:
006100 - B10.Cg-H2k Tg(NFkB/Fos-luc)26Rinc/J mice from Jackson Laboratory were used to generate
NFκB reporter BMMCs as described above. BMMCs were treated with fluoxetine and activated with
150µM ATP for 2 hours. Cells were lysed and luciferase activity was measured with the Promega
Luciferase Assay Substrate and Glomax 20/20 Luminometer (Promega). Luciferase expression is
normalized to the unactivated control.

siRNA Knock Down Experiments:
BMMCs were growth factor starved for 3 hours. 10ng/mL IL3 and SCF was added 16 hours prior
to transfection. For transfection, 3 million cells were spun down, resuspended in 100uL
transfection media (DMEM, 20% FBS, 50mM HEPES)+ 2uM siRNA (scramble control, P2X7, SERT
or P2X3 specific siRNA purchased from Qiagen), placed in transfection cuvette and
electroporated in program T-05 in the Amaxa instrument. Cells were plated at 0.5X105 cells/mL
and allowed to rest for 48 hours in cRMPI+10ng/mL IL3 and SCF. At 48 hours, cells were
collected to check knock down efficiency by protein staining via flow cytometry (P2X7 antibody
-Biolegend clone 1F11, SERT antibody-Alomone Labs cat# AMT-004). Cells were spun down in
fresh media, sensitized with IgE, treated with fluoxetine at various doses and crosslinked as
previously described.
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Western Blot:
BMMCs were treated with fluoxetine and crosslinked as described earlier. After crosslinking for
0 or 15 minutes, cells were lysed. Western blotting was performed using 50μg of total protein
per sample. Protein was loaded and separated over 4–20% gradient SDS polyacrylamide gels
(Bio–Rad, Hercules, CA). Proteins were transferred to nitrocellulose (Pall Corporation, Ann
Arbor, MI), and blocked for 60 minutes in 1% Blocker Casein (Thermofisher) in TBS plus 0.1%
Tween 20 (TBST). Blots were incubated in Casein/TBST with a 1:1000 dilution of anti-Syk, pSyk,
AKT, pAKT (Cell Signaling) overnight at 4°C with gentle rocking. Blots were washed six times for
10 minutes each in TBST, followed by incubation in Blocker Casein containing at 1:5000 dilution
of fluorescently –labeled anti–IgG (matched to the appropriate primary antibody source
species, from Cell Signaling, Danvers, MA). Size estimates for proteins were obtained using
molecular weight standards from Bio–Rad. Blots were visualized and quantified using a LiCor
Odyssey CLx Infrared imaging system. Fluorescence intensity for the protein of interest was
normalized to the signal intensity for the relevant loading control, using Image Studio 4.0 (LiCor).
HDM Sensitization, Airway Hypersensitivity and Lung Inflammation Model:
Female C57BL/6J mice were sensitized with 50g HDM (Stallergenes Greer Cat# XPB70D3A2.5,
Lot 360924) in 4mg Imject Alum (Thermofisher) daily on days 0-2. Starting on day 13, every 3
days, mice were given 25g HDM intranasally, under isoflurane anesthesia. Mice were given
PBS or fluoxetine dissolved in PBS on days 11-23 intranasally. On day 24, mice were
anesthetized and a cannula was inserted in the trachea. Mice were then subjected to forced
oscillation on a computer controlled ventilator (Flexivent system, Scireq Inc.) during increasing
nebulized methacholine exposure. BALF was collected for cytokine ELISA and cells were
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analyzed by flow cytometry. Lung lobes were either flash frozen for RNA collection, or digested
and single cell suspension was stained for flow cytometry, or fixed in 10% formalin for H&E and
PAS staining. For flow cytometry analysis, all cells were stained with Zombie aqua dye, blocked
with 2.4G2, and stained with anti-CD45, anti-FcRI, and anti-cKit for mast cells; anti-CD90.2
(Biolegend clone 30-H12)for T cells; anti-B220 (BD Bioscience clone RA3-6B2) and anti-MCH II
(BD Bioscience clone M5/114) for B cells; anti-SiglecF and anti-CCR3 (Biolegend J073E5) for
eosinophils; anti-CD3 (BD Bioscience clone 17A2), anti-CD4 (Biolegend clone GK1.5), anti-IL4,
and anti-IL13 for Th2 cells; or anti-CD11b (Biolegend clone M1/70) and anti-Ly6G(BD Bioscience
clone 1A8) for neutrophils. Cell number was determined using Precision Counting Beads as
directed by the manufacturer (BD). For re-stimulation, lung cells were plated in cRPMI with
1M ionomycin, 25ng/mL PMA and 5M monensin at 37C for 3 hours prior to staining. All
gating was determined by isotype and fluorescence minus one control. Initial gating strategy
shown in figure 21B. Th2 cells gated on CD3+CD4+ cells. Blood plasma was collected for total
IgE (Biolegend) and HDM-IgG (Condrex) by ELISA.
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Chapter 3: Results
SSRIs Suppress IgE-mediated cytokine production in BMMCs and PMCs
SSRIs have been shown to suppress LPS-mediated TNF production in macrophages 65 64. We
first tested a panel of SSRIs for effects on mast cell IgE-induced cytokine production (Fig. 4). The
drug concentrations were the highest that did not affect viability of C57BL/6J BMMCs, as
measured by PI exclusion. All 5 SSRIs suppressed cytokine production to varying degrees, with
citalopram being the least suppressive and paroxetine the most suppressive.
Inbred laboratory mice are highly genetically variable across strains78. To test the
genotypic effect on the suppression induced by SSRIs, the experiment was repeated with
BMMCs derived from BALB/cJ and 129S1/SvImJ strains (Fig. 5). 2 out of 5 SSRIs suppressed
cytokine production regardless of mice strain background. Overall, citalopram appeared to be
the least suppressive and even increased cytokine production in the BALB/cJ background.
Fluvoxamine and sertraline were also not consistently suppressive in the C57BL/6J and Balb/cJ
backgrounds respectively. Therefore, we continued to do further experimentation with
paroxetine and fluoxetine. Paroxetine did not alter degranulation in vitro or in vivo (data not
shown), therefore we focused on fluoxetine.
To determine the kinetics of fluoxetine effects, a time course was performed (Figure
6A). Fluoxetine significantly suppressed TNF production starting at 1 hour and up to 7 days of
pretreatment. To determine optimal dosage, a dose response was performed using a 24-hour
pretreatment period (Figure. 6B). At least 10M fluoxetine was needed to suppress IgEmediated cytokine secretion. This is a clinically relevant dosage for humans because tissue
concentrations of fluoxetine up to 60 M have been reported in adults, although blood
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concentrations are much lower, typically reported at 1-2uM79,80. Since mast cells are tissue
resident cells, the tissue concentrations are more relevant in this case. These conditions did not
affect BMMC viability (Figure 6C).
To begin determining how fluoxetine suppresses cytokine secretion, we measured
intracellular IL-6 by flow cytometry. As with secretion, IgE-mediated cellular IL-6 was also
suppressed by fluoxetine (Figure 7A). We then assessed cytokine gene transcription by
performing RT-qPCR for IL-6 and IL-13 mRNAs (Figure 7B). Since the induction of both cytokine
mRNAs was suppressed, we hypothesize that fluoxetine-mediated suppression is at a
transcriptional level.
Mast cell activation is multi-phasic. The late phase response includes release of newly
formed mediators such as cytokines measured in Figure 4. The early phase response involves
the release of pre-formed mediators, most of which are stored in granules. The process of
degranulation is rapid, occurring within minutes. We tested whether fluoxetine suppresses IgEmediated degranulation. BMMCs were treated with 10M fluoxetine for 24 hours, and IgE
crosslinked (IgE XL) for 30 minutes. The cells were then surface-stained with anti-CD107a, a
lysosomal marker whose cell surface expression corresponds to degranulation, and analyzed by
flow cytometry (Figure 8A). Both the percent CD107a positive and the MFI were suppressed by
fluoxetine treatment. Because degranulation is dependent on calcium influx, we tested if this
early activation event was also altered by fluoxetine (Figure 8B). We found that pretreatment
with fluoxetine significantly suppressed intracellular calcium levels. Moreover, we found that
cells exposed to fluoxetine simultaneously with antigen showed a greater reduction of calcium
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influx. These data indicate a mechanism of action that is both rapid and suppresses early FcRI
signaling events.
Mast cells produce large amounts of eicosanoids that contribute to chemotaxis and
vasodilation. Thus we measured lipids by mass spectrometry 1 hour after IgE-XL. Twenty-five
lipids were detected. Fourteen were induced by IgE XL, of which eight were altered by
fluoxetine treatment (Figure 9A). The eicosanoids induced by IgE XL but not suppressed by
fluoxetine treatment are shown in Figure 9B. We postulate that these divergent effects may be
due to selective fluoxetine effects on the enzymes involved in arachidonic acid metabolism.
Peritoneal mast cells (PMCs) are differentiated in vivo and thus provide a tool to test
whether the effects of fluoxetine on BMMCs are tied to in vitro maturation. PMCs were IgE
sensitized and treated with fluoxetine as in Figure 4 for cytokine measurement or as in Figure 7
to assess degranulation (Fig. 10A-B). Fluoxetine suppressed both cytokine production and
degranulation in PMC cultures, suggesting that these effects are not linked to in vitro
maturation.
One explanation for reduced IgE-mediated function is reduced expression of FcRI or cKit, which augments its signaling81–83 . Therefore, we measured surface FcRI and c-Kit with or
without fluoxetine treatment (Figure 11). Fluoxetine did not alter c-Kit and unexpectedly
increased FcRI expression. Therefore, reduced receptor expression is not a mechanism of
action. Measuring the signaling cascade downstream of FcεRI, we found that phosphorylation
of Syk, Btk, Akt, Erk and STAT5 were decreased by fluoxetine. Overall, these data establish that
fluoxetine suppresses early and late phase IgE-mediated mast cell activation in vitro and ex vivo,
and this affects proximal FcεRI signaling events.
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Extracellular serotonin or the serotonin transporter is not involved in fluoxetine’s
mechanism
Mast cells can produce serotonin, express several serotonin receptors and the serotonin
reuptake transporter (SERT)84. Since fluoxetine is a SERT inhibitor, we determined if increased
extracellular serotonin or SERT expression is involved in suppressing mast cell function. BMMCs
were treated with increasing doses of recombinant mouse serotonin prior to IgE XL. This had no
effect on cytokine production (Fig 12). We then tested the involvement of SERT by performing a
fluoxetine dose response in SERT deficient (KO) BMMCs (Fig 13A) and in SERT knock down (KD)
BMMCs (Fig 14). Both the KO and KD responded to fluoxetine similarly to the control BMMCs,
thus SERT expression is not required for fluoxetine-mediated suppression. Mast cell surface
markers were analyzed, and no differences were found between WT and SERT KO mast cells for
surface FcRI or c-Kit expression (Fig 13B)

P2X3 is expressed on BMMCs and is necessary for fluoxetine induced suppression
It has been previously reported that other drugs of the SSRI class can suppress P2X
receptors. Since these receptors are expressed on mast cells, we hypothesized that they are a
functional target of fluoxetine71,73. We first tested if chemical inhibition of P2X1, 3, 4, or 7 alters
IgE-mediated cytokine production and found that P2X3 inhibition via two different chemicals
caused a marked decrease in cytokine production (Figure 15). Although P2X7 inhibition did not
significantly suppress cytokine production, it trended lower. To test if fluoxetine is targeting
either P2X7 or P2X3, fluoxetine dose response was done on BMMCs after siRNA knock down of
either gene (Figure 16A). We found that P2X7 KD had no effect on fluoxetine’s ability to
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suppress IgE-induced cytokine production, while P2X3 inhibition greatly reduced fluoxetine
effects. This suggests that fluoxetine is acting through P2X3 antagonism. A possible mechanism
is downregulation of this receptor. We tested if fluoxetine treatment alters P2X3 expression
and found that after 24 hours of fluoxetine treatment, P2X3 expression is significantly
decreased (Figure 16B). Since simultaneous addition of fluoxetine and antigen caused
significant suppression of early FcRI signaling, we hypothesize that fluoxetine is suppressing
P2X3 function as well as expression.

Fluoxetine suppresses ATP-induced mast cell activation
ATP is a well-recognized DAMP signal85. Recent reports have shown that ATP can also act as a
positive feedback regulator in inflammatory states. For example, it has been shown that mice
deficient in ecto-nuclease expression have exacerbated allergic lung inflammation and allergic
dermatitis86 87. These effects have been linked to ecto-nuclease expression on mast cell and
basophil surface. Mechanistic work has shown that other innate cell types, such as eosinophils
have an autocrine LPS-ATP loop88. To test for the possibility of an ATP autocrine loop in mast
cells, ATP release was measured after IgE XL. We found a rapid release of ATP in the first
minute of XL (Fig 17). Furthermore, the addition of recombinant CD39 ATPase at the time of
stimulation reduced IgE-mediated cytokine secretion. Collectively, these data suggest that IgE
XL elicits rapid ATP release that enhances mast cell activation.
Since extracellular ATP has been reported to induce mast cell activation through P2X
receptors 4,86,87, we tested if fluoxetine can inhibit this antigen-independent activation.
Fluoxetine suppressed ATP-mediated calcium influx, degranulation, lipid production, NFB
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activity, and IL-6 production (Fig 18 C-E). These data are consistent with the theory that
fluoxetine effects could be mediated by antagonizing ATP-mediated mast cell activation
downstream of FcRI signaling.
To understand the role of P2X3 in IgE mediated signaling, we next examined IgEmediated Syk phosphorylation after treating BMMCs with P2X3 inhibitors. We found that two
different chemical inhibitors of P2X3 suppressed IgE-induced Syk phosphorylation (Figure 19).
This suggests a role for P2X3 in the early signaling events downstream FcεRI and further
supports our hypothesis.

Fluoxetine suppresses mast cell-dependent anaphylaxis in vivo
Since fluoxetine suppressed mast cells in vitro and ex vivo, we next examined in vivo
relevance. Female C57BL/6J mice were passively sensitized with anti-DNP IgE and treated with
saline or fluoxetine by IP injection. A second injection of PBS or fluoxetine was given 16 hours
later, followed by antigen injection after 2 hours. Body temperature was collected every 10
minutes (Figure 20A). Mice were sacrificed after 15 minutes to measure plasma histamine
(Figure 20B), or 2 hours to measure plasma cytokines (Figure 20C). We also subjected mice to
histamine-induced anaphylaxis to test if fluoxetine is affecting the vasculature response to
histamine, instead of acting directly on mast cells. Mice treated with PBS or fluoxetine show the
same response to histamine, suggesting that the suppressive effect is directly on mast cells
rather than vasculature (Figure 20F). Thus far, our data show that multiple parameters of mast
cell activation are suppressed by fluoxetine, in vitro and in vivo.
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Fluoxetine suppresses HDM-induced lung AHR and inflammation
Next we tested fluoxetine effects in an HDM-induced allergic lung inflammation model
that mimics some aspects of human asthma. Mice were sensitized to HDM in alum
intraperitoneally daily for three days. Starting on day 13, they were exposed to HDM
intranasally every three days. On days 11-22 the mice received PBS with or without fluoxetine
intranasally daily (Figure 21A). Sensitized mice treated with fluoxetine had significantly
decreased methacholine-induced airway responsiveness as measured by resistance (Rrs) and
elastance (Ers). Pulmonary mast cells were found in increasing number and percentage in HDMsensitized mice, an effect that was significantly reduced by fluoxetine (Figure 21B). A hallmark
of HDM lung inflammation is increased eosinophils in the BALF and lung tissue. We measured
eosinophils in the lung tissue and found that HDM did increase the number and percent of
eosinophils as expected. Fluoxetine treatment significantly suppressed eosinophil recruitment
to the lungs (Figure 21C). The overall number or percentage of lung T cells did not change with
HDM sensitization, but IL-4/IL-13 producing T cells increased in the HDM PBS group, an effect
that was also reduced by fluoxetine. In addition to pulmonary tissues, BALF analysis showed
that eosinophils, neutrophils, T and B cells were recruited to the bronchoalveolar space in mice
sensitized with HDM. Fluoxetine treatment blocked all cell recruitment (Figure 21E-G). BALF
cytokine analysis also showed significant suppression of IL-5, MIP-1, IL-13, IL-4, IL-6 and MCP-1
in fluoxetine-treated versus PBS-treated mice (Figure 21H). Total IgE and anti-HDM IgG were
increased in HDM-sensitized mice, with no difference between PBS- and fluoxetine-treated
groups. This was likely because fluoxetine treatment was not begun until mice were sensitized,
and demonstrates that even without suppressing the B cell response fluoxetine can be
beneficial in established allergic disease (Figure 21I).
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Fluoxetine and other innate immune cells
Fluoxetine effects in the HDM-induced lung model suggest that fluoxetine can suppress
other cell types. We tested fluoxetine on murine bone marrow derived basophils and
eosinophils (Figures 22 and 23). Fluoxetine suppressed IgE-induced cytokine production in
basophils inconsistently, with no changes observed in IL-4 and IL-6 production and only slight
suppression of TNF and IL-13 expression (Figure 22A). There was a consistent suppression of
CD49b expression after 24 hours pretreatment of fluoxetine, suggesting fluoxetine may
interfere with basophil maturation (Figure 22B). Further, we did not detect P2X3 expression on
mouse bone marrow derived basophils, but they did express P2X7, as previously shown by
other groups (Figure 22C)86. The lack of P2X3 expression may explain the limited fluoxetine
effects on basophil function. An elucidation on the decreased CD49b expression requires
further investigation since it is most probable to occur through a mechanism independent of
P2X3 receptor.
We show that fluoxetine can suppress ATP-induced eosinophil degranulation (Fig 23A).
Fluoxetine also decreased CCR3 expression on eosinophils (Fig 23B). CCR3 is the chemotaxis
receptor eotaxin-1 (CCL11)89 90 and has been shown to be important for eosinophil recruitment
to the lungs and intestine during type 2 inflammation 91 92. The decreased expression of CCR3
may help explain reduced eosinophilia in the mouse HDM lung inflammation model. ATPinduced cytokine production from eosinophils was undetectable. It is unknown whether
eosinophils express P2X3.
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Fluoxetine suppresses human mast cells, human mast cells express P2X3
Finally, we corroborated our mouse studies by testing fluoxetine effects on human skin
derived mast cells (HuMC; Figure 24.) IgE-induced cytokine production by HuMC from 5 donors
was significantly suppressed by fluoxetine. We measured P2X3 on human skin mast cells and
show that this receptor is expressed. Like our data with mouse mast cells, fluoxetine treatment
downregulated P2X3 expression on human skin cells as well (Figure 24). It has previously been
reported that P2X7 receptor expression is heterogenous between mast cells depending on the
tissue of maturation. For example, skin mast cells lack P2X7, but intestinal mast cells express it
abundantly87. Thus more studies need to be done to determine the heterogeneity of P2X3
expression on mast cells. These initial findings show that skin-derived mast cells can be
suppressed by fluoxetine, supporting further study of this SSRI for its ability to reduce allergic
inflammation.
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Figures

Figure 4 Panel of SSRIs suppress C57BL/6 BMMCs: A) BMMC, pre-sensitized with
Dinitrophenyl (DNP)-specific IgE, were cultured in cRPMI + IL-3/SCF (10ηg/ml) with
fluoxetine=fluox (10μM), sertraline=sertra (2μM), fluvoxamine=flovox(8μM),
paroxetine=parox (5μM), citalopram=citalo(30μM) or vehicles, for 24hrs. DNP was added at
50ηg/ml for 16hrs. IgE XL= IgE-DNP crosslinked. Supernatant cytokines were measured by
ELISA. Data shown are representative of two independent experiments in triplicates.
Statistical value determined by ANOVA comparing each drug to its respective crosslinked
vehicle control (Dunnet test). *p<.0332; **p<.0021;***p<.0002 ****p<.0001
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129/SV

BALB/c

Figure 5: SSRIs Tested on
Balb/c and 129/sv BMMCs.
BMMCs were derived from
129S1/Sv (left) or BALB/cJ (right)
mice and treated as in 4A. Data
shown are representative of two
independent experiments in
triplicates. Statistical value
determined by ANOVA,
comparing each drug to its
respective crosslinked vehicle
control (Dunnet test). *p<.0332;
**p<.0021;*** <.0002
****p<.0001. No asterisk or
NS=not significant.
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Figure 6 Fluoxetine Kinetics and Viability: A) BMMCs were treated with 10M fluoxetine for the indicated time points
pre-cross linkage. For time points longer than 24 hours, cells were washed and plated with fresh fluoxetine every 2 days. 24
hours before IgE XL, cells received IgE, overnight. The cells were washed and re-plated with fresh fluoxetine, and DNP-HSA
was added to crosslink for 16 hours. Fluoxetine treated group is compared to its media control for statistics. B) Cells were
treated as in A for 24 hours with 20, 10, 5, 2.5 or 0 M fluoxetine, cells were collected for PI exclusion in (C) and
supernatant was used for cytokine analysis with ELISA. Each timepoint is compared to crosslinked untreated control for
statistics. All experiments represented of 2 or 3 independent repeats done with triplicates. Statistical value determined by
One-way ANOVA (Dunnet test). *p<.0332; **p<.0021;***p<.0002 ****p<.0001
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Figure 7 Intracellular and mRNA cytokine levels: A)Fluoxetine-treated BMMCs were
activated by IgE XL for 2 hours, treated with monensin for 5 hours, then fixed in
paraformaldehyde, permeabilized in saponin buffer, stained for intracellular IL-6 and analyzed
by FACSCelesta. Data are from 1 experiment done in triplicate. B) Fluoxetine-treated BMMCs
were crosslinked for 4 hours and RNA was collected using Trizol. Ct values are normalized to
actin controls. Data is pooled from two independent experiments done in triplicate. Statistical
value determined by One-way ANOVA. *p<.0332; **p<.0021;***p<.0002; ****p<.0001
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Figure 8 Fluoxetine Suppresses IgE-mediated Degranulation and Calcium Influx: A) BMMCs were
treated with fluoxetine at 10M for 24 hours, then activated by IgE XL for 30min. Cells were stained for
CD107a and analyzed by FACSCelesta. Data are representative of three independent experiments done in
triplicate. B) Cells were treated as in (A), loaded with fura2 for 40 min at 37 degrees, washed and plated in
96-well plates. Cells were allowed to rest at room temp for 30 min and then at 37 degrees for 10 min prior
to activation. Cells were activated and analyzed by Flexstation plate reader every 4 seconds. Data were
collected for a minute to establish baseline, then cells were activated with DNP alone or DNP+fluoxetine for
360 seconds. Data are pooled from 2 independent experiment done in triplicate. Statistical value
determined by ANOVA and AUC. *p<.0332; **p<.0021;***p<.0002 ****p<.0001
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Figure 9 Fluoxetine Suppresses IgE-induced Inflammatory Lipid Secretion: Fluoxetine-treated
BMMCs were IgE crosslinked for 1 hour and supernatant was analyzed for eicosanoid production by
mass spectrometry. Data are pmole/4 million cells. A) Heat-map represents mean of lipids from 3
populations. B) Lipids that are induced by IgE XL and altered by fluoxetine treatment. Data are
representative of two independent experiments done in triplicate. Statistical value determined by oneway ANOVA. *p<.0332; **p<.0021;***p<.0002 ****p<.0001
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9C

Figure 9C Fluoxetine Suppresses IgE-induced Inflammatory Lipid Secretion: Lipids from figure
9A, that are induced by IgE XL but not altered by fluoxetine treatment. Statistical value determined by
one-way ANOVA. *p<.0332; **p<.0021;***p<.0002 ****p<.0001
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Figure 11 Fluoxetine Suppresses IgE induced signaling: Surface receptors were stained after 24
hour treatment of fluoxetine at 10M. Data are from a single experiment done in triplicate. BMMCs were
treated with fluoxetine and IgE for 24 hours, washed, and crosslinked in the presence of fluoxetine, for 10
mins. Activation was stopped with the addition of paraformaldehyde. Cells were permeabilized with
methanol, stored in 4 degrees overnight and stained and analyzed by FACScelesta. Western blot cell
lysates were obtained from cells treated the same way. Data are representative of two independent
experiments done in triplicates. Statistical value determined by unpaired student t-Test for surface
markers, one way ANOVA for phosphor-proteins. *p<.05; **p<.001; ****p<.0001 for t-Test. *p<.0332;
**p<.0021;***p<.0002 ****p<.0001 for one-way ANOVA
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Figure 12 Serotonin pretreatment of BMMCs: BMMCs pre-sensitized with IgE were treated with 0, 50,
100 or 400 ng/ml of recombinant mouse serotonin for 24 hours, crosslinked and supernatant was analyzed for
cytokine by ELISA. Data are representative of 4 independent experiments done in triplicates. Statistical value
determined by one-way ANOVA.NS=not significant
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A.

B.

Figure 13 Fluoxetine Dose Response on SERT Deficient BMMCs. A)BMMCs were derived from WT and
SERT KO mice. Cells were presensitized with IgE and fluoxetine dose response was performed. Cells were
activated for 16 hours and supernatant was collected for cytokine analysis.B) Surface staining by
FACSCelesta. Data is pooled from 3 independent experiments done in triplicates. Statistical value determined
by ANOVA or student T test in (B).
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Figure 14 Fluoxetine dose response on siRNA induced SERT KD BMMCs . BMMCs were
transfected with scramble control and SERT specific siRNA. 72 hours later, KD efficiency was determined
by flow cytometry and cells were sensitized with IgE overnight. The next day, a dose response was done
with fluoxetine for 24 hours and cells were activated for 16 hours. Data is pooled from 3 independent
repeats done in triplicates. Statistical value determined by one way ANOVA. *p<.0332;
**p<.0021;***p<.0002 ****p<.0001
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Figure 15 P2X Inhibitor Effects on cytokine production in BMMCs. BMMCs were sensitized with IgE overnight, and
treated with NF449, 5BDB, A70003, TCP262 (10uM), and RO-3(7.5uM) for 24 hours and then treated with DNP for 16 hours.
Data are pooled from 2 independent experiments done in triplicates. Statistical value determined by ANOVA. *p<.0332;
**p<.0021;***p<.0002 ****p<.0001
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Figure 16 Fluoxetine dose response on P2X7 or P2X3 knock down BMMCs. BMMCs were transfected
with scramble control, P2X7 or P2X3 specific siRNA. KD efficiency was determined 72 hour post transfection.
Cells were treated as in figure 14. Data is representative of 3 independent experiments done in triplicate.
Statistical value determined by ANOVA or student T test for protein expression. *p<.0332;
**p<.0021;***p<.0002 ****p<.0001
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Figure 16B P2X3 Expression on BMMCs after fluoxetine treatment. BMMCs were treated with
10uM fluoxetine for 24 hours and stained for P2X3 by flow cytometry. Data is from 1 experiment with
three populations, in duplicates. Statistical value determined by ANOVA. *p<.0332;
**p<.0021;***p<.0002 ****p<.0001
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A.

B.

Figure 17 IgE induced ATP release and ATPase effects on IgE induced cytokine
production. A) BMMCs were sensitized with IgE overnight, activated for 60 seconds and the cells
were filtered out of the supernatant. ATP was measured using a luminescent ATP measuring kit.
B) BMMCs were sensitized with IgE overnight, and activated with or without CD39 for 16 hours.
Supernantant was collected for ELISA for cytokine measurement. Data is pooled from 2
independent experiments. Statistical value determined by ANOVA. *p<.0332;
**p<.0021;***p<.0002 ****p<.0001
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Figure 18 Fluoxetine Suppresses ATP mediated BMMC Activation. BMMCs were treated with 10µM
fluoxetine for 24 hours and activated with 300µM ATP for calcium influx, A, for 15 minutes for degranulation, B ,
150µM for 1 hour for lipid production, 2 hour for reporter activity, 4 hours for IL-6 production, E. A,B,D,E are
pooled from two or more independent experiments done in triplicates. C is a representative of 2 independent
experiment done in triplicate or quadruplicates. Statistical value determined by ANOVA. *p<.0332;
**p<.0021;***p<.0002 ****p<.0001
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Figure 19 P2X3 Inhibition Suppresses phosphorylation of Syk. IgE sensitized BMMCs were treated with
RO-3 (7.5uM) or TCP262 (1uM) for 1 or 24 hours before IgE cross linkage. P-Syk was measured by flow
cytometry. Black histogram plot represents IgE XL Vehicle, blue histogram plot represents IgE XL inhibitor
treated. Data is representative of two independent experiments done in triplicates. Statistical value determined
by ANOVA. *p<.0332; **p<.0021;***p<.0002 ****p<.0001
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Figure 20 Fluoxetine Suppress Mast cell function in vivo. Mice were sensitized with DNP-IgE i.p. and
treated with PBS or fluoxetine. The next day mice received a second dose of PBS or fluoxetine. 2 hours later
there they i.p. injected with DNP. Core body temperature (A, N=13/group) was taken every 10 mins post
DNP injection for 1 hour and 30 mins for the reminder hour. Mice were euthanized at 2 hours and plasma
was collected for cytokine analysis (B, N=10/group). Some mice were euthanized at 30 mins for plasma
histamine analysis (B, N=10/group) Statistical value determined by ANOVA and area under the curve +
student T test in A. *p<.0332; **p<.0021;***p<.0002 ****p<.0001
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Figure 20D Histamine Induced Anaphylaxis. Mice were treated with two doses of
fluoxetine or PBS at 1kg/mg daily. Two hours after the last dose, 5mg of histamine was
administered, i.p. Core body temperature was measured as in fig. 20A. N=10/group. Statistical
value determined by area under the curve and student T test . *p<.05; **p<.001; ****p<.0001.
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Figure 21A Mouse HDM-AHR model
Mice were sensitized with HDM in Alum intraperitoneally, three days consecutively. Starting on day 11 mice
were treated daily with fluoxetine or PBS intranasally. On days 13, 16 and 19, were challenged with intranasal
HDM. Mice were subjected to flexivent on day 23 and sacrificed for data collection.
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Figure 21B HDM induced lung resistance. Methacholine induced lung resistance was measured in
anesthetized mice on the Scrieq flexivent instrument. Data is pooled from 2 independent experiments,
n=8/group. Statistics determined by AUC and one way ANOVA. *p<.0332; **p<.0021;***p<.0002
****p<.0001
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Figure 21C Lung Mast Cells. Data is pooled from 2 independent experiments, each experiment with 4 or 5 mice in each
group. Statistical value determined by ANOVA. *p<.0332; **p<.0021;***p<.0002 ****p<.0001
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Figure 21D Lung Eosinophils. Data is pooled from 3 independent experiment with 4-5 mice in each group per
experiment. Statistical value determined by ANOVA. *p<.0332; **p<.0021;***p<.0002 ****p<.0001
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Figure 21E Lung T cells. Data is pooled from 3 independent experiment with 4-5 mice in each group
per experiment. Statistical value determined by ANOVA. *p<.0332; **p<.0021;***p<.0002 ****p<.0001
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Figure 21F BALF Eosinophils. Data is pooled from 3 independent experiment with 4-5 mice in each group.
Statistical value determined by ANOVA. *p<.0332; **p<.0021;***p<.0002 ****p<.0001
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Figure 21G BALF Neutrophils. Data is pooled from 2 independent experiment with 4-5 mice in each group. Statistical value
determined by ANOVA. *p<.0332; **p<.0021;***p<.0002 ****p<.0001
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Figure 21H BALF Lymphocytes. Data is
pooled from 2 independent experiment with
4-5 mice in each group. Statistical value
determined by ANOVA. *p<.0332;
**p<.0021;***p<.0002 ****p<.0001
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Figure 21I BALF Cytokines. Data is pooled from 3 or 4 independent experiment with 4-5 mice in
each group. Statistical value determined by ANOVA. *p<.0332; **p<.0021;***p<.0002
****p<.0001.
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Figure 21J Plasma Ig Levels. Data is pooled from 2 independent experiment with 4-5 mice in each
group per experiment. Statistical value determined by ANOVA and student T test. *p<.0332;
**p<.0021;***p<.0002 ****p<.0001
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Figure 22 Basophils. Basophils were grown in 20ng/mL IL3 in cRMPI. On day 6 cells were sensitized with IgE. On
day 7 cells were washed and media was replenished. Cells were plated at 1X106 cells/mL with or without 10uM or
20 uM fluoxetine. 24 hours later cells were activated with DNP-HSA. Two hours into activation cells were treated
with 5 uM monensin for 5 hours. Cells were stained for CD49b and P2X7 and fixed in 4% formaldehyde and stored
in PBS overnight. Cells were then permealized with saponin buffer and stained for intracellular cytokines and P2X3.
A is from one experiment with 5 populations, each plated in duplicates, two independent repeats showed variable
suppression of cytokines (independent repeat shown on the next page). B is from two independent experiments
with 5 or 3 populations analyzed in duplicates, crosslinked and uncrosslinked samples showed no difference and
are pooled. C is from 3 populations from 1 experiment. Statistical value determined by ANOVA and student T test.
*p<.0332; **p<.0021;***p<.0002 ****p<.0001
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Figure 22D Basophils. Basophils were grown in 20ng/mL IL3 in cRMPI. On day 6 cells were sensitized
with IgE. On day 7 cells were washed and media was replenished. Cells were plated at 1X106 cells/mL
with or without 10uM or 20 uM fluoxetine. 24 hours later cells were activated with DNP-HSA. Two hours
into activation cells were treated with 5 uM monensin for 5 hours. Cells were stained for CD49b and
P2X7 and fixed in 4% formaldehyde and stored in PBS overnight. Cells were then permealized with
saponin buffer and stained for intracellular cytokines and P2X3. A is from one experiment with 5
populations, each plated in duplicates, two independent repeats showed variable suppression of
cytokines (independent repeat shown on previous next page). Statistical value determined by ANOVA
and student T test. *p<.0332; **p<.0021;***p<.0002 ****p<.0001
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Figure 23 Eosinophils. Bone marrow derived eosinophils were treated with increasing dosage of fluoxetine for 24
hours then activated with 300uM ATP for 15 minutes. Cells were stained with zombie aqua dye to indicate live cells,
surface stained and analyzed by flow cytometry. FLX=fluoxetine. Data is representative of two independent repeats with
three populations, each in duplicates. Statistical value determined by ANOVA and student T test. *p<.0332;
**p<.0021;***p<.0002 ****p<.0001
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Figure 24 Human Mast cells HuMC were treated with IgE and fluoxetine at 10µM for 24 hours. Cells were
washed, fluoxetine was re-added and crosslinked with DNP for 16 hours. Cytokines were measured by ELISA.
P2X3 staining was measured by FACS. Cytokine data is from two independent experiments. P2X3 staining is a
combination of 3 donors. Statistical value determined paired student T test. *p<.05; **p<.001; ****p<.0001.
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Figure 25 P2X3 Expression in male vs. female BMMCs. BMMCs derived from balb/c male or female mice were
stained with anti-P2X3 or rabbit IgG isotype control and analyzed by flow cytometry. Data is combined from two
independent experiments conducted with three populations from
67 each gender, each stained in duplicates. Statistical
value determined by ANOVA Tukey’s multiple comparisons analysis. *p<.0332; **p<.0021;***p<.0002 ****p<.0001

Chapter 4: Discussion
Fluoxetine is an SSRI, a class of anti-depressants that are widely prescribed. It has been
found by numerous studies to have fewer side effects compared to other anti-depressants. This
leads to higher compliance. Its long half-life, 3-4 days for fluoxetine and 7-10 days for the active
metabolite, norfluoxetine, protects against withdrawal phenomenon. The safety of this drug is
reviewed in this cited meta-analysis93. Many studies show that SSRIs have immunosuppressive
properties, although no work has been done to test their effectiveness in allergic disease. We
show that fluoxetine can suppress of all phases of IgE-induced mast cell activation, specifically
release of granules, and the production of eicosanoids and cytokines. Fluoxetine can also
suppress IgE-independent mast cell activation with ATP. Extracellular ATP has been shown to
accumulate in the airways of human asthmatics and mouse models of asthma94 and to induce
mast cell degranulation and cytokine production4,36,37. We show that fluoxetine can block both
modes of mast cell activation at the signaling levels; fluoxetine suppressed FcRI-mediated
phosphorylation events and ATP-induced NFB activation. Further, these effects were
consistent in vivo using models of anaphylaxis and airway inflammation.
We show that fluoxetine effects are not mast cell-restricted, since it also suppressed
ATP-mediated eosinophil degranulation. Eosinophils are effector cells with potent granular
mediators that can cause tissue damage if release is uncontrolled, as in allergic inflammation95.
It is known that inflamed tissues have high extracellular ATP present that can potentiate
eosinophil activation and recruitment. Eosinophils can be activated by extracellular ATP in the
asthmatic airways through P2X1 signaling. Interestingly rather than degranulation or cytokine
production, P2X1 has been shown to mediate eosinophil adhesion 96. Another study shows that
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ATP can induce eosinophil migration into the peritoneal cavity of rats97. Human eosinophils
were also shown to migrate towards ATP in vitro98. Thus fluoxetine effects on eosinophils has
clinical relevance.
We found that fluoxetine can reduce multiple parameters of HDM-induced airway
hyperresponsiveness and inflammation. More importantly, it suppressed allergic inflammation
in sensitized mice, after a B cell response has already begun. Allergic rhinitis and allergic asthma
affect 15% and 11% of the US population, respectively99 7. Current treatments have limited
efficacy or high costs (anti-IgE treatment) that limit clinical use or patient access. Leukotriene
receptor antagonists100 show improvement in lung function in 35-50% of patients. Inhaled
corticosteroids are considered first line treatment for moderate to severe asthma, however in a
clinical setting, inhaled corticosteroids and leukotriene receptor antagonists show similar
effectiveness101. Given the results of this study and fluoxetine’s high capacity to concentrate in
tissues79,80 where mast cells reside and many allergens are first encountered, fluoxetine may be
a viable option for allergy therapy, perhaps in combination with other treatments.
Furthermore, because fluoxetine treatment improved both AHR and inflammation, it may help
circumvent the issues with current treatment options that show effectiveness in only one or the
other.
We reveal that fluoxetine appears to act by antagonizing P2X3 expressed on BMMCs
and human skin mast cells. Since two different inhibitors of P2X3 significantly suppressed IgEmediated mast cell function, this is a logical target for further study both from the perspective
of understanding its role in mast cell function and for developing new therapeutics. P2X3
inhibitors are already an interest of pharmacological companies. The P2X3 inhibitor, gefapixant,
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has been in phase 2 clinical trials for chronic cough. Our study suggests that this drug should be
tested for treatment of mast cell related disease. Very little is currently known about P2X3
function on mast cells. Early studies screening mast cells for P2X expression did not identify
P2X3. There could be many reasons P2X3 was undetected. First, this study used PCR, and
primers may miss certain isoforms. There are 6 different isoforms of P2X3 currently known.
Second, this study scanned the LAD2 cell line for expression and only confirmed positive hits
with primary cells. It is possible that this cell line does not produce P2X3 but primary mast cells
do. Further, LAD2 cells are of male origin. We have data suggesting that mast cells of male
background have little to no P2X3 expression compared to female mast cells (Figure 25). All our
human mast cells are of female origin. This is backed up by several studies finding that P2X3
expression and function is controlled by estrogen in humans and mice102–104. Interestingly, mice
lacking estrogen receptor alpha and beta show decreased P2X3 expression on sensory
neurons105.
A limitation of our study is that ATP activation is not specific for P2X3, rather all P2X
receptors on mast cells are responding to this stimulus. Given that mast cells express at least 4
P2X receptors, and there is no naturally occurring ligand that selectively activates P2X3, we
cannot exclude contributing stimuli from other P2X receptors without knockouts of each. We
attempted to minimize activation of P2X7 in our studies by using a relatively low ATP dose of
150 M or 300 M. P2X7 has a lower affinity for ATP than P2X3, so it requires a much higher
dose to become activated106. However, our evidence that fluoxetine can suppress this nonspecific stimulus may make it a strong drug candidate, since ATP will likely act on several
receptors at a given time. Continued studies will utilize P2X3 KO mice, mast cell-specific P2X3
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KO mice, and mast cell-specific P2X1,4,7 KO mice. There are many unanswered questions. We
do not know how or why P2X3 inhibition suppresses Syk phosphorylation, which is one of the
earliest steps in FcRI signaling. We do not know if P2X3 on mast cells has signaling capacities
outside of calcium influx. We also do not know how P2X3 expression is regulated on mast cells,
including how fluoxetine reduces its surface levels.
Another limitation is that we have not assessed the mechanism of suppression in HDMinduced lung inflammation. It is unlikely that P2X3 suppression alone caused the broad
suppression of nearly all parameters we measured. It is interesting to note that some studies
show that blocking ATP in mouse models of asthma with ATPase causes significant suppression
of AHR and lung inflammation94,107. Some clues from the literature show that fluoxetine can
suppress Th1 development61. This may also be true for Th2 cells, and our data may support this
since Th2 numbers in the lungs were lower in the fluoxetine treated mice. However, further
studies need to be conducted to verify this hypothesis.
Overall, we show that fluoxetine suppresses IgE- and ATP-mediated mast cell activation.
We show that potent lipid mediators, cytokines and degranulation are all attenuated by this
FDA-approved drug. This is true for human mast cells, as well as other innate immune cells and
is consistent in relevant in vivo models. We show for the first time that human skin mast cells
express P2X3, and that P2X3 inhibition may be a viable therapeutic target for allergies and mast
cell related disorders. These data offer a new understanding of how FcRI function may be
enhanced by rapid ATP secretion that forms a positive feedback loop via P2X3, and suggest that
suppressing P2X3 may provide clinical benefit to allergic disease.
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Figure 26 Summary figure
We show that fluoxetine treatment attenuates IgE-mediated signaling, calcium influx, degranulation and
cytokine production. Our data suggests a positive feedback loop via the ATP-P2X3 axis. The findings of
this study support the hypothesis that fluoxetine blocks this positive feedback loop to diminish IgE
mediated mast cell activation.
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